Mylan to Pay $465 Million in EpiPen Settlement

The Wall Street Journal reports that Mylan agreed today to a $465 million settlement with the U.S. Department of Justice and other agencies over the classification of its anti-allergy EpiPen Auto-Injector under the Medicaid Drug Rebate program.

The full article (subscription required) is here.

Leave a Reply

Your email address will not be published. Required fields are marked *